000135978 001__ 135978
000135978 005__ 20240704095849.0
000135978 0247_ $$2doi$$a10.3389/fimmu.2024.1387454
000135978 0248_ $$2sideral$$a138961
000135978 037__ $$aART-2024-138961
000135978 041__ $$aeng
000135978 100__ $$aPeralta Alvarez, Marco Polo
000135978 245__ $$aLow-dose M.tb infection but not BCG or MTBVAC vaccination enhances heterologous antibody titres in non-human primates
000135978 260__ $$c2024
000135978 5060_ $$aAccess copy available to the general public$$fUnrestricted
000135978 5203_ $$aIntroduction: Mycobacteria are known to exert a range of heterologous effects on the immune system. The mycobacteria-based Freund’s Complete Adjuvant is a potent non-specific stimulator of the immune response used in immunization protocols promoting antibody production, and Mycobacterium bovis Bacille Calmette Guérin (BCG) vaccination has been linked with decreased morbidity and mortality beyond the specific protection it provides against tuberculosis (TB) in some populations and age groups. The role of heterologous antibodies in this phenomenon, if any, remains unclear and under-studied.
Methods: We set out to evaluate antibody responses to a range of unrelated pathogens following infection with Mycobacterium tuberculosis (M.tb) and vaccination with BCG or a candidate TB vaccine, MTBVAC, in non-human primates.
Results: We demonstrate a significant increase in the titer of antibodies against SARS-CoV-2, cytomegalovirus, Epstein-Barr virus, tetanus toxoid, and respiratory syncytial virus antigens following low-dose aerosol infection with M.tb. The magnitude of some of these responses correlated with TB disease severity. However, vaccination with BCG administered by the intradermal, intravenous or aerosol routes, or intradermal delivery of MTBVAC, did not increase antibody responses against unrelated pathogens.
Discussion: Our findings suggest that it is unlikely that heterologous antibodies contribute to the non-specific effects of these vaccines. The apparent dysregulation of B cell responses associated with TB disease warrants further investigation, with potential implications for risk of B cell cancers and novel therapeutic strategies.
000135978 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000135978 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000135978 700__ $$aJones, Holly
000135978 700__ $$aRedondo Azema, Hugo
000135978 700__ $$aDavis, Chloe
000135978 700__ $$aWhite, Andrew D.
000135978 700__ $$aSarfas, Charlotte
000135978 700__ $$aDennis, Mike
000135978 700__ $$aLi,Shuailin
000135978 700__ $$aWright, Daniel
000135978 700__ $$aPuentes, Eugenia
000135978 700__ $$aKimuda, Simon
000135978 700__ $$aBelij-Rammerstorfer, Sandra
000135978 700__ $$0(orcid)0000-0001-7897-9173$$aAguilo, Nacho$$uUniversidad de Zaragoza
000135978 700__ $$0(orcid)0000-0003-2993-5478$$aMartin, Carlos$$uUniversidad de Zaragoza
000135978 700__ $$aSharpe, Sally
000135978 700__ $$aMcShane, Helen
000135978 700__ $$aTanner,Rachel
000135978 7102_ $$11011$$2630$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Microbiología
000135978 7102_ $$11011$$2566$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Inmunología
000135978 773__ $$g15 (2024), [12 pp.]$$pFront. immunol.$$tFrontiers in Immunology$$x1664-3224
000135978 8564_ $$s8939967$$uhttps://zaguan.unizar.es/record/135978/files/texto_completo.pdf$$yVersión publicada
000135978 8564_ $$s2048297$$uhttps://zaguan.unizar.es/record/135978/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000135978 909CO $$ooai:zaguan.unizar.es:135978$$particulos$$pdriver
000135978 951__ $$a2024-07-04-07:59:28
000135978 980__ $$aARTICLE